UPDATE: New Data Now Confirms Valeant’s Undisclosed SEC Investigation


Valeant Pharmaceuticals International, Inc.  $VRX 

Sunday Special UPDATE:  Last week, on 23-Feb-2016, we published a report warning of the potential for a new and undisclosed SEC probe of Valeant.  In a letter dated 22-Feb-2016, and just received by us on Saturday via US Mail, the SEC has now confirmed Valeant’s involvement in on-going enforcement proceedings that remain undisclosed as of this date.   All we know about the SEC probe at this time is that it somehow pertains to the conduct, transactions, and/or disclosures of Valeant Pharmaceuticals.   

To access the full report, simply click on the PDF posted here.  Documents, when available, are also accessible by clicking on the links.

To learn more about our research process, including how to best use this information in your own decision-making, click here.

Our Terms of Service, trading policy, relevant disclosures, and other legal notices can be found here.  

Copyright Warning and Notice

The works of authorship contained in the accompanying material, including but not limited to all data, design, text, images, charts and other data compilations or collective works are owned by Probes Reporter, LLC or one of its affiliates and may not be copied, reproduced, transmitted, displayed, performed, distributed, rented, sublicensed, altered, or stored for subsequent use, in whole or in part in any manner, without the prior written consent of Probes Reporter, LLC.

Photocopying or electronic distribution of any of the accompanying material or contents without the prior written consent of Probes Reporter, LLC violates U.S. copyright law, and may be punishable by statutory damages of up to $150,000 per infringement, plus attorneys’ fees (17 USC 504 et. seq.). Without advance permission, illegal copying includes regular photocopying, faxing, excerpting, forwarding electronically, and sharing of online access.


Probes Reporter, LLC is not an investment adviser and does not offer or provide personalized investment advice. The information in our reports and appearing on ProbesReporter.com is not a solicitation connected to any security. The information we provide is obtained from company submissions and our own Freedom of Information requests made to the Securities and Exchange Commission. No representation or warranty is made as to the timeliness or completeness of any information found in our reports or on ProbesReporter.com.

Probes Reporter does not adopt the truth or falsity of the contents of any of the documents or filings referred to on this website, and no conclusion of wrongdoing should be inferred from the fact that an investigation has been initiated by the SEC. Probes Reporter is not the guarantor of any investment and cannot be held liable for any losses or expenses incurred as a result of reliance upon any information contained herein, and ProbesReporter.com is not a substitute for your own due diligence, which may include advice from an investment professional.

With few exceptions, Probes Reporter, LLC prohibits its employees and principals from trading of any kind in any individual public company securities, or derivatives thereof, on any company on which production of any new research report has commenced.  Such prohibitions shall remain in place until either 5 days after the individual research report has been published or its production otherwise ceases.   

Probes Reporter, LLC does not engage in investment banking activities or take any security positions, except those necessary for routine corporate treasury functions

Our full trading policy, along with our Terms of Service, relevant disclosures, and other legal notices can be found here.  

Intellectual Property

© 2016 Probes Reporter, LLC. All rights reserved.  Probes Reporter®; They Know it.  Now You Know It.®; Better Disclosure for Better Decisions®; Disclosure Insight®;  and, Disclosure Games®, are all registered trademarks of Probes Reporter, LLC and are proprietary.